Macque
马克
基本信息
- 批准号:8516869
- 负责人:
- 金额:$ 135.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-01 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS VaccinesAdjuvantAdultAgeAgonistAllelesAnimal ModelAnimalsAntibodiesAntibody AffinityAntibody FormationAntigensArtsAutopsyB-Cell DevelopmentB-LymphocytesBindingBiological PreservationBiopsyBloodBreedingCD4 Positive T LymphocytesCaringCellsCellular biologyClinicalClinical ChemistryCollectionCommunicationControl AnimalDNADevelopmentDiagnosticDoseEnsureEuthanasiaEvaluationExperimental DesignsFemaleFutureGenderGoalsGranulocyte-Macrophage Colony-Stimulating FactorHIVHIV InfectionsHIV vaccineHelper-Inducer T-LymphocyteHematologyHistologicImmuneImmune responseImmunityImmunizationImmunologicsIn VitroInfectionInfection preventionInfluenzaInstructionInvestigationLaboratoriesMacacaMacaca mulattaMediatingModelingMonitorMonkeysMusOrganPathogenicityPathologicPerformancePhysical ExaminationPlayPre-Clinical ModelPrimatesProcessProteinsResearchResearch PersonnelResourcesRetroviridaeRouteSIVSIV VaccinesSalivaSamplingServicesSimian T-lymphotropic virus 1SourceSpecimenTestingTissue SampleToll-like receptorsVaccinesVaginaVaginal DouchingViralViremiaVirusanimal caredesignenvironmental enrichment for laboratory animalslymph nodesneutralizing antibodynonhuman primatenovelplasmid DNApreventprogramsprotective effectrectalresearch studyresponsesample collectionsuccesstargeted deliverytissue processingtransmission processvaccine developmentvaccine efficacy
项目摘要
The long-range goal of this Program Project is to develop vaccine strategies against mucosal SIV (and HIV in the future) transmission, with a special focus on identifying local and systemic mechanisms leading to protective B cell development and antibody production. The objectives for the Primate Core are to provide the experimental animals and support services needed to facilitate the efficient completion of the aims outlined in Project 1, 2, 3 and 4.
This will include the provision of retrovirus-free adult female rhesus macaques from the Yerkes rhesus macaque breeding colonies; immunizations using the various immunization platforms (Projects 1 and 2) sample collections (for all projects) and repeated low dose vaginal challenges with SIVsmE660. The Primate Core tasks also include daily monitoring ofthe experimental animals; periodic physical examinations with blood collections for immunologic and virologic evaluations and procurement/shipment of samples to the Program Project investigators; the performance of CBCs and laboratory analyses as needed; Perform euthanasia with sample collection and processing for Projects 3 and 4; and the performance of a basic gross and histologic necropsy evaluations of all experimental animals that die or are sacrificed during the course of this study.
Provision of these resources and support services will facilitate the development and testing of novel AIDS vaccine concepts proposed in this Program Project. The Primate Core will play a key role in the development of a vaccine to prevent mucosal transmission and pathogenicity of SIV and HIV and the determination Of correlates of such protection. Vaccine efficacy will be evaluated by its ability to 1) prevent acquisition of infection (sterilizing immunity) or 2) significant control of viremia post-challenge and preservation of protective immune responses.
该计划项目的远程目标是制定针对粘膜SIV(和将来的艾滋病毒)传播的疫苗策略,特别着重于识别局部和系统机制,从而导致保护性B细胞开发和抗体生产。灵长类动物核心的目标是提供实验动物和支持服务,以促进项目1、2、3和4中概述的目标的有效完成。
这将包括提供无逆转录病毒的成年雌性恒河猕猴,这些猕猴是猕猴猕猴繁殖菌落的;使用各种免疫平台(项目1和2)采样收集(用于所有项目)的免疫接种,并重复使用SIVSME660进行的低剂量阴道挑战。灵长类动物的核心任务还包括对实验动物的每日监测;通过收集血液的定期进行身体检查,以进行免疫和病毒学评估,并向计划项目调查人员运送样品的采购/运输;根据需要进行CBC和实验室分析的性能;对项目3和4进行样本收集和处理,进行安乐死;以及在本研究过程中对所有死亡或牺牲的实验动物进行基本的总体和组织学尸检评估的表现。
提供这些资源和支持服务将有助于该计划项目中提出的新型艾滋病疫苗概念的开发和测试。灵长类动物核心将在开发疫苗中发挥关键作用,以防止SIV和HIV的粘膜传播和致病性以及确定这种保护的相关性。疫苗功效将通过其能力1)防止感染的能力进行评估(消毒免疫)或2)挑战后对病毒血症的显着控制并保存保护性免疫反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Francois J Villinger其他文献
Francois J Villinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Francois J Villinger', 18)}}的其他基金
Expansion of Macaque Breeding runs at the New Iberia Research Center
新伊比利亚研究中心扩大猕猴繁育规模
- 批准号:
10761902 - 财政年份:2023
- 资助金额:
$ 135.62万 - 项目类别:
“Renovation of Building 29 laboratories at the New Iberia Research Center"
– 翻新新伊比利亚研究中心的 29 栋实验室”
- 批准号:
10547926 - 财政年份:2022
- 资助金额:
$ 135.62万 - 项目类别:
Novel Macaque Breeding Runs at the New Iberia Research Center
新伊比利亚研究中心开展新型猕猴育种工作
- 批准号:
10374603 - 财政年份:2021
- 资助金额:
$ 135.62万 - 项目类别:
相似国自然基金
穿透性靶向胰腺癌内cDC1的纳米佐剂调控溶酶体逃逸促进放疗诱导ICD的机制研究
- 批准号:82303680
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
展示PD-L1抗体的纳米锰佐剂联合放疗以诱导原位肿瘤疫苗的产生及其机制的探究
- 批准号:32371518
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
应用于冠状病毒广谱疫苗开发的新型全链式免疫增强型佐剂研究
- 批准号:82341036
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
相似海外基金
HIV Vaccines Clinical Trials Network Leadership and Operations Center
HIV 疫苗临床试验网络领导和运营中心
- 批准号:
10311601 - 财政年份:2021
- 资助金额:
$ 135.62万 - 项目类别:
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
舌下注射疫苗预防婴儿经口艾滋病毒传播
- 批准号:
10172886 - 财政年份:2018
- 资助金额:
$ 135.62万 - 项目类别:
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
舌下注射疫苗预防婴儿经口艾滋病毒传播
- 批准号:
10425465 - 财政年份:2018
- 资助金额:
$ 135.62万 - 项目类别:
Development of Lipid-based Nanoparticle Vaccines Against Mycobacterium tuberculosis
抗结核分枝杆菌脂质纳米颗粒疫苗的研制
- 批准号:
9298853 - 财政年份:2017
- 资助金额:
$ 135.62万 - 项目类别: